Identifying the translational gap in the evaluation of drug-induced QTc interval prolongation

British Journal of Clinical Pharmacology

Volumn 76, Issue 5, 2013, Pages 708-724

  Chain, Anne S Y ^a   Dubois, Vincent F S ^a   Danhof, Meindert ^a   Sturkenboom, Miriam C J M ^b   Della Pasqua, Oscar ^a,c  

^a LEIDEN UNIVERSITY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Model based drug development; Pre clinical studies; QTc interval prolongation; Translational science

Indexed keywords

CISAPRIDE; LAMOTRIGINE; MOXIFLOXACIN; PLACEBO; SOTALOL;

ADULT; ANIMAL EXPERIMENT; ANTIARRHYTHMIC ACTIVITY; ARTICLE; BAYES THEOREM; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTRICAL PARAMETERS; FEMALE; HUMAN; MALE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PHASE 1 CLINICAL TRIAL; POTENTIAL DIFFERENCE; PRIORITY JOURNAL; PROBABILITY; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TELEMETRY;

MODEL-BASED DRUG DEVELOPMENT; PRE-CLINICAL STUDIES; QTC INTERVAL PROLONGATION; TRANSLATIONAL SCIENCE;

ADOLESCENT; ADULT; ANIMALS; AZA COMPOUNDS; BAYES THEOREM; CISAPRIDE; CROSS-OVER STUDIES; DOGS; DOUBLE-BLIND METHOD; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROBABILITY; QUINOLINES; SINGLE-BLIND METHOD; SOTALOL; SPECIES SPECIFICITY; TRANSLATIONAL MEDICAL RESEARCH; YOUNG ADULT;

EID: 84886896617     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12082     Document Type: Article

References (41)

1. Darpo B, Nebout T, Sager PT. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. J Clin Pharmacol 2006; 46: 498-507.
2. ICH Expert Working Group. ICH Harmonised tripartite guideline. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrythmic Potential for Non-Antiarrythmic Drugs 2005.
3. Danhof M, de Lange EC, Della Pasqua OE, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci 2008; 29: 186-191.
4. ICH Expert Working Group. ICH Harmonised tripartite guideline. S7A Safety pharmacology studies for human pharmaceuticals, 2000.
5. ICH Expert Working Group. ICH Harmonised tripartite guideline. S7B The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals, 2005.
6. Fleury A, Lave T, Jonsson F, Schmitt M, Hirkaler G, Polonchuk L, Breidenbach A. A pharmacokinetic-pharmacodynamic model for cardiovascular safety assessment of R1551. J Pharmacol Toxicol Methods 2011; 63: 123-133.
7. Zareba W. Drug induced QT prolongation. Cardiol J 2007; 14: 523-533.
8. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-1022.
9. Cavero I, Mestre M, Guillon JM, Crumb W. Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin Pharmacother 2000; 1: 947-973.
10. Hammond TG, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Redfern WS, Sullivan AT, Camm AJ. Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey. Cardiovasc Res 2001; 49: 741-750.
11. Netzer R, Ebneth A, Bischoff U, Pongs O. Screening lead compounds for QT interval prolongation. Drug Discov Today 2001; 6: 78-84.
12. Malik M, Andreas JO, Hnatkova K, Hoeckendorff J, Cawello W, Middle M, Horstmann R, Braun M. Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine. Clin Pharmacol Ther 2008; 84: 595-603.
13. Piotrovsky V. Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. AAPS J 2005; 7: E609-624.
14. Vandemeulebroecke M, Lembcke J, Wiesinger H, Sittner W, Lindemann S. Assessment of QT(c)-prolonging potential of BX471 in healthy volunteers. A 'thorough QT study' following ICH E14 using various QT(c) correction methods. Br J Clin Pharmacol 2009; 68: 435-446.
15. Chain AS, Krudys KM, Danhof M, Della Pasqua O. Assessing the probability of drug-induced QTc-interval prolongation during clinical drug development. Clin Pharmacol Ther 2011; 90: 867-875.
16. Gabrielsson J, Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, 3rd edn. Stockholm: Swedish Pharmaceutical Press, 2001; 275-280.
17. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - A Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000; 10: 325-337.
18. Spiegelhalter D, Thomas A, Best N, Gils W. BUGS: Bayesian Inference Using Gibbs Sampling, Version 1.4.1. Cambridge: MRC Biostatistics Unit, 2003.
19. Lunn DJ, Best N, Thomas A, Wakefield J, Spiegelhalter D. Bayesian analysis of population PK/PD models: general concepts and software. J Pharmacokinet Pharmacodyn 2002; 29: 271-307.
20. Duffull SB, Kirkpatrick CM, Green B, Holford NH. Analysis of population pharmacokinetic data using NONMEM and WinBUGS. J Biopharm Stat Comput 2005; 15: 53-73.
21. Bachman DM. Oral magnesium ion shortens prolonged QTc interval. J Clin Psychiatry 2003; 64: 733-734.
22. Kovács SJ Jr. The duration of the QT interval as a function of heart rate: a derivation based on physical principles and a comparison to measured values. Am Heart J 1985; 110: 872-878.
23. Spiegelhalter DAK, Myles J. Bayesian Approaches to Clinical Trials and Health Care Evaluations. New York: Wiley, 2004.
24. Spiegelhalter D, Best N, Carlin B. Bayesian measures of model complexity and fit. J R Stat Soc 2002; 64: 583-639.
25. Brooks SPG. A General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 1998; 7: 434-455.
26. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian Data Analysis. London: Capman & Hall, 2003.
27. Gelman AR. Inference from iterative simulation using multiple sequences. Stat Sci 1992; 7: 457-472.
28. Jonker DM, Kenna LA, Leishman D, Wallis R, Milligan PA, Jonsson EN. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data. Clin Pharmacol Ther 2005; 77: 572-582.
29. Ollerstam A, Visser SA, Persson AH, Eklund G, Nilsson LB, Forsberg T, Wiklund SJ, Gabrielsson J, Duker G, Al-Saffar A. Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs. J Pharmacol Toxicol Methods 2006; 53: 174-183.
30. Dodds MG, Hooker AC, Vicini P. Robust population pharmacokinetic experiment design. J Pharmacokinet Pharmacodyn 2005; 32: 33-64.
31. Nyberg J, Karlsson MO, Hooker AC. Simultaneous optimal experimental design on dose and sample times. J Pharmacokinet Pharmacodyn 2009; 36: 125-145.
32. Salvi V, Karnad DR, Panicker GK, Natekar M, Hingorani P, Kerkar V, Ramasamy A, de Vries M, Zumbrunnen T, Kothari S, Narula D. Comparison of 5 methods of QT interval measurements on electrocardiograms from a thorough QT/QTc study: effect on assay sensitivity and categorical outliers. J Electrocardiol 2011; 44: 96-104.
33. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003; 58: 32-45.
34. De Ponti F, Poluzzi E, Montanaro N. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol 2001; 57: 185-209.
35. Milnes JT, Witchel HJ, Leaney JL, Leishman DJ, Hancox JC. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: cisapride versus dofetilide. J Pharmacol Toxicol Methods 2010; 61: 178-191.
36. Davie C, Pierre-Valentin J, Pollard C, Standen N, Mitcheson J, Alexander P, Thong B. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel. J Cardiovasc Electrophysiol 2004; 15: 1302-1309.
37. Martin RL, McDermott JS, Salmen HJ, Palmatier J, Cox BF, Gintant GA. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J Cardiovasc Pharmacol 2004; 43: 369-379.
38. Gintant GA. Regional differences in IK density in canine left ventricle: role of IKs in electrical heterogeneity. Am J Physiol 1995; 268: H604-613.
39. Antzelevitch C, Sicouri S, Litovsky SH, Lukas A, Krishnan SC, Di Diego JM, Gintant GA, Liu DW. Heterogeneity within the ventricular wall. Electrophysiology and pharmacology of epicardial, endocardial, and M cells. Circ Res 1991; 69: 1427-1449.
40. Soloviev MV, Hamlin RL, Barrett RM, Chengelis CP, Schaefer GJ. Different species require different correction factor for the QT interval. Cardiovasc Toxicol 2006; 6: 51-52.
41. Markert M, Shen R, Trautmann T, Guth B. Heart rate correction models to detect QT interval prolongation in novel pharmaceutical development. J Pharmacol Toxicol Methods 2011; 64: 25-41.